Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1181 to 1190 of 1864 total matches.
A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B)
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018 (Issue 1539)
schedule, with doses given on day 0, day 7, and day 21-30, and a booster dose given at month 12.
HB ...
The FDA has approved a two-dose hepatitis B virus
(HBV) vaccine (Heplisav-B – Dynavax) for use in adults
≥18 years old. The three other HBV vaccines marketed
in the US are usually administered in 3 doses. Engerix-B
and Recombivax HB are licensed for use in persons of
all ages. A combination hepatitis A/B vaccine (Twinrix)
contains the same hepatitis B component as Engerix-B
and is licensed for use only in adults.
Desmopressin (Nocdurna and Noctiva) for Nocturnal Polyuria
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019 (Issue 1568)
hour
before to 8 hours after taking the drug. The cost of
30 days’ treatment with either strength ...
The FDA has approved a sublingual tablet (Nocdurna –
Ferring) and a nasal spray (Noctiva – Avadel) formulation
of desmopressin acetate for treatment of nocturia due to
nocturnal polyuria in adults who wake up ≥2 times per
night to void. Nocdurna and Noctiva are the first two
products to be approved in the US for this indication.
Higher-strength nasal spray and oral tablet formulations
of desmopressin (DDAVP, and others) have been available
for years for treatment of diabetes insipidus and primary
nocturnal enuresis (bedwetting in children). In 2007, the
indication for primary...
Rimegepant (Nurtec ODT) for Acute Treatment of Migraine
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
). The safety of
treating >15 migraine attacks in a 30-day period with
rimegepant has not been established ...
The FDA has approved an orally disintegrating tablet
(ODT) formulation of rimegepant (Nurtec ODT –
Biohaven), a small-molecule calcitonin gene-related
peptide (CGRP) receptor antagonist ("gepant"), for
acute treatment of migraine with or without aura
in adults. Rimegepant is the second oral gepant to
become available in the US; ubrogepant (Ubrelvy),
which is approved for the same indication, was the
first. Four parenteral CGRP antagonists, erenumab
(Aimovig), fremanezumab (Ajovy), galcanezumab
(Emgality), and eptinezumab (Vyepti), are approved
for prevention of...
MenQuadfi - A New Meningococcal (A, C, W, and Y) Vaccine
The Medical Letter on Drugs and Therapeutics • May 17, 2021 (Issue 1624)
) to ≥1:16 (day 30; ≥1:8 in Chang et al), or a ≥4-fold increase
at day 30 from a baseline of ≥1:8 ...
The FDA has licensed MenQuadfi (Sanofi Pasteur),
a quadrivalent polysaccharide conjugate vaccine
that uses tetanus toxoid as a protein carrier, for
prevention of invasive meningococcal disease caused
by Neisseria meningitidis serogroups A, C, W, and Y
(MenACWY) in persons ≥2 years old.
Azstarys (Serdexmethylphenidate/Dexmethylphenidate) for ADHD
The Medical Letter on Drugs and Therapeutics • Oct 04, 2021 (Issue 1634)
days. They were evaluated at 8 time points over
a 13-hour period using the SKAMP rating scale, a
13 ...
The FDA has approved a long-acting fixed-dose
combination of the stimulant dexmethylphenidate
and the prodrug serdexmethylphenidate (Azstarys –
Corium) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years
old. Azstarys is the first product containing serdexmethylphenidate
to become available in the US.
Tramadol/Celecoxib (Seglentis) for Pain
The Medical Letter on Drugs and Therapeutics • Apr 18, 2022 (Issue 1648)
in additive effects. Use of a monoamine oxidase
(MAO) inhibitor with or within 14 days of tramadol ...
The FDA has approved Seglentis (Esteve/Kowa), an
oral combination of tramadol hydrochloride, a weak
opioid agonist and weak serotonin and norepinephrine
reuptake inhibitor (SNRI), and celecoxib, a COX-2
selective nonsteroidal anti-inflammatory drug
(NSAID), for use in adults with acute pain that is
severe enough to require an opioid and for which
alternative treatment options are inadequate.
Rosiglitazone/Glimepiride (Avandaryl) for Diabetes
The Medical Letter on Drugs and Therapeutics • Mar 13, 2006 (Issue 1230)
mg once 29.10
Amaryl (Aventis) (max 8 mg) 38.70
1. Cost of 30 days’ treatment (8 mg/d ...
Avandaryl, a new fixed-dose tablet combining the thiazolidinedione rosiglitazone (Avandia) and the sulfonylurea glimepiride (Amaryl, and others), was recently approved by the FDA for treatment of type 2 diabetes. It is approved for patients already taking a combination of rosiglitazone and a sulfonylurea or those not adequately controlled on rosiglitazone or sulfonylurea monotherapy. Rosiglitazone is also available in a fixed-dose combination with metformin (Avandamet). Most patients with type 2 diabetes eventually require 2 drugs with different mechanisms to control...
Telavancin (Vibativ) for Gram-Positive Skin Infections
The Medical Letter on Drugs and Therapeutics • Jan 11, 2010 (Issue 1329)
4.50
Bactrim DS (Mutual) 7.41
1. Cost of 1 day’s treatment of a 70 kg patient according to AWP ...
Telavancin (Vibativ - Astellas and Theravance), a lipoglycopeptide derivative of vancomycin (Vancocin, and others), has received FDA approval for treatment of complicated skin and skin structure infections caused by susceptible gram-positive bacteria in adults.
Vanzacaftor, Tezacaftor, and Deutivacaftor (Alyftrek) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • Mar 17, 2025 (Issue 1724)
mg/60 mg/150 mg once/day in patients ...
The FDA has approved Alyftrek (Vertex), an oral
fixed-dose combination of the cystic fibrosis
transmembrane conductance regulator (CFTR)
modulators vanzacaftor, tezacaftor, and deutivacaftor,
for once-daily treatment of cystic fibrosis (CF) in
patients ≥6 years old who have at least one F508del
mutation or another responsive mutation in the
CFTR gene. This is the first approval for vanzacaftor
and for deutivacaftor, a deuterated form of ivacaftor.
Trikafta, a twice-daily oral fixed-dose combination of
elexacaftor, tezacaftor, and ivacaftor, is FDA-approved
for the same indication...
Med Lett Drugs Ther. 2025 Mar 17;67(1724):41-3 doi:10.58347/tml.2025.1724a | Show Introduction Hide Introduction
In Brief: Lowering the Dose of Lunesta
The Medical Letter on Drugs and Therapeutics • Jun 09, 2014 (Issue 1444)
occur.
1. FDA Drug Safety Communication. FDA warns of next-day
impairment with sleep aid Lunesta ...
The FDA has required the manufacturer of eszopiclone (Lunesta – Sunovion), a benzodiazepine receptor agonist approved for the treatment of insomnia, to lower the current recommended starting dose to 1 mg for both men and women because a new study found that an evening dose of 3 mg can impair driving skills, memory, and coordination for more than 11 hours.1 Eszopiclone’s half-life is longer than that of any other drug in its class, which includes zolpidem (Ambien, and generics) and zaleplon (Sonata, and generics).All benzodiazepine receptor agonists may impair performance the next morning,...